Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,321 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01351571 | An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma | completed | — | 5 | Hoffmann-La RocheINDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT03161145 | A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread | completed | — | 297 | Bristol-Myers SquibbINDUSTRY | 1 |
| Oct 3, 2017 |
| clinicaltrials |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer(SUNRISES) | terminated | Phase 2 | 41 | Associació per a la Recerca Oncologica, SpainOTHER | 3 | Oct 2, 2017 | clinicaltrials |
| NCT00003520 | Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00923845 | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2017 | clinicaltrials |
| NCT03292549 | RObotic PArtial Nephrectomy National Study(ROPAN) | completed | — | 452 | University Hospital, BordeauxOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01521715 | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma(FLIPPER) | completed | Phase 4 | 44 | iOMEDICO AGINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | terminated | Phase 2 | 6 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.OTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02429440 | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides(UroRCC) | unknown | Phase 1 / Phase 2 | 40 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT00089778 | Vaccine Treatment of Kidney Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02080650 | Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) | completed | N/A | 62 | Duke UniversityOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01598038 | Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma | terminated | N/A | 41 | Centre Francois BaclesseOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
| NCT00496587 | Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT01514448 | Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | completed | Phase 4 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 17, 2017 | clinicaltrials |
| NCT03218319 | Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)(VAPANCR) | unknown | N/A | 200 | University Hospital, AngersOTHER_GOV | 0 | Jul 14, 2017 | clinicaltrials |
| NCT01236053 | Cancer in Patients With Gabapentin (GPRD) | completed | — | 2,323,608 | GlaxoSmithKlineINDUSTRY | 0 | Jul 6, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00357760 | Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 2 | Jun 23, 2017 | clinicaltrials |
| NCT02883153 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 30 | Radboud University Medical CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00537056 | Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI | completed | N/A | 17 | Stanford UniversityOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma(5-AZ) | terminated | Phase 1 / Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | terminated | N/A | 20 | University of ChicagoOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01908166 | Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions | completed | N/A | 61 | Stanford UniversityOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01189370 | Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | completed | Phase 2 | 25 | University of Kansas Medical CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT02150369 | Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms | completed | — | 32 | Duke UniversityOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT03033186 | Everolimus TDM to Predict Long Term Toxicity(Foresight) | unknown | — | 40 | Maastricht University Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00835978 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | completed | Phase 2 | 213 | PfizerINDUSTRY | 6 | May 30, 2017 | clinicaltrials |
| NCT00899860 | Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer | terminated | — | 30 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01138124 | Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) | completed | — | 54,202 | GlaxoSmithKlineINDUSTRY | 0 | May 30, 2017 | clinicaltrials |
| NCT02988219 | Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method | completed | Phase 4 | 50 | Medical University of WarsawOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03149523 | Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors(ExhauCRF) | unknown | — | 150 | European Georges Pompidou HospitalOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT01462214 | Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer | completed | Phase 1 / Phase 2 | 96 | Hans J. van der Vliet, MD, PhDOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT02330783 | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | unknown | Phase 2 | 106 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00425386 | Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 2 | 60 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT02160600 | Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial | completed | N/A | 124 | All India Institute of Medical SciencesOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT03129724 | Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 0 | Apr 26, 2017 | clinicaltrials |
| NCT00401128 | Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 9 | The Cleveland ClinicOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT01613846 | Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) | completed | Phase 3 | 544 | Technical University of MunichOTHER | 3 | Apr 20, 2017 | clinicaltrials |
| NCT00004095 | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 38 | Northwestern UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00405366 | Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer(NRR) | completed | Early Phase 1 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01064310 | Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer(PISCES) | completed | Phase 3 | 169 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 17, 2017 | clinicaltrials |
| NCT00184015 | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | unknown | Phase 1 / Phase 2 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | terminated | Phase 2 | 10 | Sandy SrinivasOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00971620 | Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 7, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2017source: clinicaltrials